<DOC>
	<DOCNO>NCT02710084</DOCNO>
	<brief_summary>This pilot study examine efficacy , safety tolerability intranasal oxytocin novel treatment Phelan-McDermid syndrome ( PMS ) . This study utilize randomize , placebo-controlled design 12 week ( phase 1 ) , follow open-label extension 12 week ( phase 2 ) . The purpose evaluate effect intranasal oxytocin impairment attention , social memory , socialization , language , repetitive behavior .</brief_summary>
	<brief_title>Piloting Treatment With Intranasal Oxytocin Phelan-McDermid Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Chromosome Deletion</mesh_term>
	<mesh_term>Chromosome Disorders</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>Inclusion criterion : Have diagnosis PhelanMcDermid syndrome define pathogenic deletion mutation SHANK3 gene confirm chromosomal microarray sequencing . Must age 5 17 Must stable medication psychosocial therapy regimen least three month prior enrollment Exclusion criterion : Allergy oxytocin Active cardiovascular disease , epilepsy , renal disease control medication Pregnant , lactate refuse practice contraception sexually active Have caretaker unable speak English , consistently present visit report symptom , otherwise judge unable comply protocol study team Comorbid condition patient medically compromise participate</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>